Does the recent Board decision in Ex parte Kubin mean the end for biotech patents claiming DNA sequences?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ex parte Kubin, 83 USPQ2d 1410 (Bd. Pat. App. & Int. 2007).
Kubin, et al. Eur. J. Immunol. 29, 3466–3477 (1999).
US Patent No. 5,688,690 (1997).
Sambrook, J., Fritsch, E. & Maniatis, T. Molecular Cloning: A Laboratory Manual, edn. 2 (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989).
Mathew, P.A. et al. J. Immunol. 151, 5328–5337 (1993).
In re Deuel, 51 F.3d 1552 (Fed. Cir. 1995).
KSR International Co. v. Teleflex Inc., 550 U.S.___, 127 S.Ct. 1727 (2007).
Teitelbaum, R. & Cohen, M. Nat. Biotechnol. 25, 1105–1106 (2007).
Federal Register 72, 57526–57535 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamanaka, M. A nail in the coffin for DNA sequence patents?. Nat Biotechnol 26, 1085–1086 (2008). https://doi.org/10.1038/nbt1008-1085
Issue Date:
DOI: https://doi.org/10.1038/nbt1008-1085
This article is cited by
-
Combine and conquer: handling biotech combination inventions in the wake of KSR
Nature Biotechnology (2009)
-
DNA sequence patents are not in the grave yet
Nature Biotechnology (2009)